

# Criteria-Based Consultation Prescribing Program KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR DRUG COVERAGE

## liraglutide (Saxenda)

### Notes:

- Saxenda is covered under the prescription drug benefit for weight loss **ONLY for Kaiser Northwest members with coverage for medications used to treat weight loss**. Others pay member cash price.
- Contact Pharmacy Services in your home region to confirm your benefits for weight loss medications.
- Quantity Limits: Yes
- ^ Adequate trial is defined as a 3-month treatment duration
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

**Initiation (new start) criteria for adult patients for chronic weight management:** Non-formulary **liraglutide (Saxenda)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; AND
- No personal or family history of medullary thyroid carcinoma (MTC) or Multi Endocrine Neoplasia syndrome type 2 (MEN 2)
- Diagnosis for chronic weight management; AND
- Patient is 18 years of age or older; AND
- Patient's current weight and BMI are documented in the encounter in which liraglutide (Saxenda) is ordered; AND
- Patient is currently following a diet and exercise program; AND
- BMI greater than or equal to 30 kg/m<sup>2</sup> or BMI greater than or equal to 27 kg/m<sup>2</sup> AND has at least one of the following comorbid conditions documented:
  - Hypertension
  - Diabetes
  - Hyperlipidemia
- AND-
- Patient has failed an adequate trial^ to at least two of the following medications or medication combination therapies, or patient has an allergy, intolerance, or contraindication to all the following therapies:
  - phentermine
  - diethylpropion
  - topiramate
  - phentermine + topiramate or phentermine/topiramate (Qsymia)
  - naltrexone + bupropion or naltrexone/bupropion (Contrave)

kp.org

Revised: 5/8/25  
Effective: 7/3/25

All plans offered and underwritten by  
Kaiser Foundation Health Plan of the Northwest

# Criteria-Based Consultation Prescribing Program KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR DRUG COVERAGE

## liraglutide (Saxenda)

### **-AND-**

- Patient has then failed an adequate trial or has an allergy, intolerance, or contraindication to semaglutide (Ozempic/Wegovy)

**Initiation (new starts) criteria for pediatric patients for obesity:** Non-formulary **liraglutide (Saxenda)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; **AND**
- No personal or family history of medullary thyroid carcinoma (MTC) or Multi Endocrine Neoplasia syndrome type 2 (MEN 2)
- Diagnosis of class 2 or class 3 obesity; **AND**
- Patient is 12 to 17 years of age and is at least Tanner 2; **AND**
- Patient's current weight and BMI are documented within the last month from the date in which liraglutide (Saxenda) is ordered; **AND**
- Patient is currently following a diet and exercise program **AND**
- BMI greater than or equal to 35 kg/m<sup>2</sup> or greater than or equal to 120% of the 95<sup>th</sup> percentile

### **-AND-**

- Patient has failed an adequate trial<sup>^</sup> to at least two of the following medications or medication combination therapies, or patient has an allergy, intolerance, or contraindication to all the following therapies:
  - phentermine
  - topiramate
  - phentermine + topiramate or phentermine/topiramate (Qsymia)

### **-AND-**

- Patient has then failed an adequate trial or has an allergy, intolerance, or contraindication to semaglutide (Ozempic/Wegovy)

# Criteria-Based Consultation Prescribing Program KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR DRUG COVERAGE

## liraglutide (Saxenda)

**Continued use criteria (every 12 months) for patients previously reviewed and approved when used for chronic weight management/obesity:** Non-formulary **liraglutide (Saxenda)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient's updated weight and BMI are recently documented; **AND**
- Achieved and maintained 5% or greater weight loss after starting liraglutide (Saxenda)

**Criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary **liraglutide (Saxenda)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; **AND**
- Patient is using for chronic weight management/obesity